A study shows that blocking CD47 can enhance the antitumor effect of trastuzumab in breast cancer and that the expression of tumor-related cytokine CD47 was inversely correlated with survival in breast cancer patients with HER2+. Here, ERBB2 is linked to breast carcinoma.